TABLE 5.
Change from baseline of mean FACE-Q scores used in combined treatment studies.
| ARTICLE | Hibler, 2016 JDD27 | Bertossi, 2020 JCD28 | Qureshi, 2017 Aesth Plastic Surg30 | Iorio, 2012 Aesth Plastic Surg31 | The Harmony Study (Narurkar, 2016; Weinkle; 2018; Cohen, 2021)32-34 | Kaminer 2019 Derm Surg35 (The Harmony Study: Post-Hoc analysis) |
|||
| PRODUCT | Injectables: Filler and BTX (n=16) Laser (n=14) | Laser (n=14) | Vycross™ products ONA | BTX: (INCO vs. ONA) (n= 12) Filler: Juvederm XC, Belotero, Radiesse (n=18), Both (n=15) | BTX: ABO HA filler: Restylane (n=11) | Filler Facial Lines and Folds: HYC-24L/L+ (n=96), Volume restoration: VYC-20 (n=96) ONA (n=96) Bimatoprost (n=100) | Same as “The Harmony Study” | ||
| TREATMENT SITE | Face, not specified further | Face | Upper face (n=224), Midface (n=250), Lower face (n=158), ONA (n=250) | BTX: FH, GL, CF Filler: TT, Lips, NLF, MA, MB |
Filler: NLF, MA, LMF, NB | HYC-24L/L+: NLF, OC, POL, ML, RCL VYC-20: midface ONA: GL and CF | Same as “The Harmony Study" | ||
| INJECTION TECHNIQUE | NR | NR | Injection and cannula | NR | – | Mixed: Linear threading, serial puncture, fanning | – | ||
| VOLUME USED | NR | NR | Total: 14 syringes 20- 34 yrs old: 10 syringes 35-49 yrs old; 15 syringes ≥ 50 yrs old: 18 syringes | Filler: 1 mL, BTX: 40 U | BTX: 40 U | VYC-20L (initial 2.4 mL; touch up 1.2mL, total 3.1) OC: 1.1 mL ML: 1.2 mL RCL: 0.8 mL NLF: 1.6 mL POL: 0.9 mL ONA 50 U |
Highest site: VYC-20L: 2.6 mL HYC-24L/L+: 4.0mL OC: 0.9 mL ML: 1.2 mL RCL: 0.0 mL NLF: 2.0 mL POL: 0.8 mL |
Lowest Site: VYC20L: 2.9 mL HYC-24L/L+: 3.4 mL OC: 1.0 mL ML: 1.1 mL RCL: 0.8 mL NLF: 1.2 mL POL: 0.6 mL |
|
| FOLLOW UP | NR | NR | 3 months s/p single treatment |
1 Month s/p single treatment |
1 Week s/p single treatment |
4 months s/p initial treatment |
4 months s/p initial treatment |
4 months s/p initial treatment |
|
| CHANGE FROM BASELINE OF MEAN FACE-Q SCORE | SATISFACTION WITH FACIAL APPEARANCE | 21.3* | 26.7* | NR | 16.1* | 3.5* | 31.7* | Highest Site | Lowest Site |
| 13.8 | 9.1 | ||||||||
| SATISFACTION WITH FACIAL SKIN | 20.4* | 26.1* | NR | NR | NR | NR | NR | NR | |
| APPRAISAL OF FACIAL LINES | 7.2 | 17.0 | NR | NR | NR | NR | NR | NR | |
| PSYCHOLOGICAL WELLBEING | NR | NR | 18.2 | 34.6* | NR | 19.9* | 8.2 | 5.1 | |
| SOCIAL FUNCTIONING SOCIAL CONFIDENCE | NR | NR | NR | 26.9* | NR | 18.2* | 7.3 | 4.2 | |
| AGING APPEARANCE APPRAISAL | NR | NR | NR | 20.4* | NR | 28.5* | 8.7 | 4.2 | |
| AGE APPRAISAL VAS | NR | NR | NR | NR | NR | -4.6 years (improved) | -6.3 years (improved) | -3.4 years (improved) | |
*Significant (p<0.05) compared to baseline. Vycross™ products used include VYC-20 Voluma®, VYC-17.5 Volift®, VYC-15 Volbella®, or VYC-12, Volite®.
ABO: AbobotulinumtoxinA; BTX: Botulinumtoxin A; CF: Crow’s feet; GL: Glabella; FH: Forehead; INCO: IncobotulinumtoxinA; LMF: Labiomental folds; MA: Malar area; MB: Mandibular border; ML: Marionette lines; NA: Not applicable; NB: Nasal Bridge; NLF: Nasolabial fold, NR: not reported; OC: Oral commissures; ONA: Onabotulinum toxin A; POL: Perioral lines; RCL: Radial cheek lines; TT: Tear Trough; VYC-20L: Juvéderm Voluma® XC with Lidocaine; VYC-25: Juvéderm Volux® with Lidocaine; U: Units